Table 2. Characteristics of patients included in randomized controlled trials that compared the effects of SGLT2 inhibitors versus placebo on hard clinical outcomes. Trials in patients with renal impairment or heart failure are still ongoing (except CREDENCE recently published) (13).
| Patients | Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin | Sotagliflozin |
|---|---|---|---|---|---|
| T2DM with established CVD (2° prevention) | CANVAS (65%) | DECLARE-TIMI 58 (40%) | EMPA-REG OUTCOME (>99%) | VERTIS-CV (>99%) | NA |
| T2DM with other CV risk factors (1° prevention) | CANVAS (35%) | DECLARE-TIMI 58 (60%) | NA | NA | NA |
| Renal impairment | CREDENCE | DAPA-CKD* | EMPA-KIDNEY* | NA | SCORED |
| Heart failure (reduced LVEF) | NA | DAPA-HF* | EMPEROR (reduced)* | NA | SOLOIST-WHF |
| Heart failure (preserved LVEF) | NA | DELIVER* | EMPEROR (preserved)* | NA | NA |
*, these trials included both patients with and without T2DM. CV, cardiovascular; CVD, cardiovascular disease; LVEF, left ventricular ejection fraction; NA, not available yet; T2DM, type 2 diabetes mellitus.